Weekly Digest – October 2025 Weekly Digest – October 2025 23 October 2025: Heidelberg Pharma’s lead ADC Candidate HDP-101 granted fast track designation by US FDA for the treatment of multiple myeloma The US FDA granted fast track designation to […]
Weekly Digest – October 2025 Weekly Digest – October 2025 21 October 2025: Takeda enters global strategic partnership with Innovent Biologics to bolster oncology pipeline with next-generation investigational medicines for treatment of solid tumors Takeda entered a global strategic partnership […]
Weekly Digest – October 2025 Weekly Digest – October 2025 12 October 2025: Sacituzumab tirumotecan (Sac-TMT) approved for marketing for third indication by the National Medical Products Administration in EGFRm NSCLC following progresssion on EGFR-TKI therapy Sichuan Kelun-Biotech announced that its […]
Weekly Digest – October 2025 Weekly Digest – October 2025 13 October 2025: TQB2102 HER2 bispecific ADC included in the Breakthrough Therapeutic Designation process TQB2102, a HER2 bispecific antibody-drug conjugate (ADC) developed by Sino Biopharmaceutical, has been granted Breakthrough Therapeutic Designation (BTD) by China’s CDE for […]
Weekly Digest – October 2025 Weekly Digest – October 2025 13 October 2025: Mabwell’s CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA Mabwell’s CDH17-targeting ADC, 7MW4911, received IND clearance from China’s NMPA to begin clinical trials in patients with advanced solid […]
Weekly Digest – October 2025 Weekly Digest – October 2025 14 October 2025: DualityBio DB-1324 project received clinical trial approval from HREC and TGA in Australia DualityBio announced that its DB-1324, a next-generation ADC developed using its Duality Immune Toxin Antibody […]
Weekly Digest – October 2025 Weekly Digest – October 2025 15 October 2025: Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio Boehringer Ingelheim and AimedBio have entered a global collaboration and licensing agreement to co-develop a novel antibody-drug conjugate […]
Weekly Digest – October 2025 Weekly Digest – October 2025 17 October 2025: Hansoh Pharma grants Roche an exclusive license to novel CDH17-targeting ADC HS-20110 Hansoh Pharma has granted Roche an exclusive worldwide license (excluding Mainland China, Hong Kong, Macau, and Taiwan) to its investigational CDH17-targeting […]
Weekly Digest – October 2025 Weekly Digest – October 2025 07 October 2025: ENHERTU plus Pertuzumab supplemental New Drug Application submitted in Japan as first-line therapy for patients with HER2 positive metastatic breast cancer Daiichi Sankyo has submitted a supplemental […]
Weekly Digest – October 2025 Weekly Digest – October 2025 09 October 2025: Adcendo ApS announces FDA Fast Track Designation granted to ADCE-D01 for the treatment of soft tissue sarcoma US FDA has granted Fast Track designation to Adcendo’s ADCE-D01, […]
